These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33812245)

  • 1. In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms.
    Almulla AF; Al-Rawi KF; Maes M; Al-Hakeim HK
    J Affect Disord; 2021 May; 287():316-326. PubMed ID: 33812245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.
    Mousa RF; Al-Hakeim HK; Alhaideri A; Maes M
    Metab Brain Dis; 2021 Jan; 36(1):169-183. PubMed ID: 32965599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.
    Al-Dujaili AH; Mousa RF; Al-Hakeim HK; Maes M
    Schizophr Bull; 2021 Mar; 47(2):530-541. PubMed ID: 32971537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and κ and μ Opioid Receptors Are Associated with Interleukin-6.
    Moustafa SR; Al-Rawi KF; Stoyanov D; Al-Dujaili AH; Supasitthumrong T; Al-Hakeim HK; Maes M
    Diagnostics (Basel); 2020 Aug; 10(9):. PubMed ID: 32858974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition.
    Kanchanatawan B; Thika S; Anderson G; Galecki P; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt C):168-176. PubMed ID: 28666826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways.
    Almulla AF; Al-Hakeim HK; Abed MS; Carvalho AF; Maes M
    Schizophr Res; 2020 Aug; 222():342-353. PubMed ID: 32467068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major neurocognitive psychosis: a novel schizophrenia endophenotype class that is based on machine learning and resembles Kraepelin's and Bleuler's conceptions.
    Maes M
    Acta Neuropsychiatr; 2023 Jun; 35(3):123-137. PubMed ID: 36373497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study.
    Kanchanatawan B; Thika S; Sirivichayakul S; Carvalho AF; Geffard M; Maes M
    Neurotox Res; 2018 Apr; 33(3):641-655. PubMed ID: 29380275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde.
    Maes M; Sirivichayakul S; Kanchanatawan B; Carvalho AF
    World J Biol Psychiatry; 2020 Jun; 21(5):383-401. PubMed ID: 32031479
    [No Abstract]   [Full Text] [Related]  

  • 10. In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy.
    Al-Hakeim HK; Mousa RF; Al-Dujaili AH; Maes M
    Metab Brain Dis; 2021 Jun; 36(5):939-955. PubMed ID: 33580860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowered serum cesium levels in schizophrenia: association with immune-inflammatory biomarkers and cognitive impairments.
    Almulla AF; Moustafa SR; Al-Dujaili AH; Al-Hakeim HK; Maes M
    Braz J Psychiatry; 2021; 43(2):131-137. PubMed ID: 32556004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia.
    Kanchanatawan B; Sriswasdi S; Maes M
    Metab Brain Dis; 2019 Feb; 34(1):267-282. PubMed ID: 30467771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.
    Maes M; Sirivichayakul S; Matsumoto AK; Maes A; Michelin AP; de Oliveira Semeão L; de Lima Pedrão JV; Moreira EG; Barbosa DS; Geffard M; Carvalho AF; Kanchanatawan B
    Mol Neurobiol; 2020 May; 57(5):2333-2345. PubMed ID: 32040834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions.
    Sirivichayakul S; Kanchanatawan B; Thika S; Carvalho AF; Maes M
    CNS Neurol Disord Drug Targets; 2019; 18(2):124-140. PubMed ID: 30451122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach.
    Al-Jassas HK; Al-Hakeim HK; Maes M
    J Affect Disord; 2022 Jan; 297():233-245. PubMed ID: 34699853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia.
    Almulla AF; Al-Hakeim HK; Maes M
    CNS Spectr; 2021 Aug; 26(4):368-377. PubMed ID: 32431263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia.
    Al-Hakeim HK; Almulla AF; Al-Dujaili AH; Maes M
    Curr Top Med Chem; 2020; 20(9):747-758. PubMed ID: 31994463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.
    Al-Hakeim HK; Al-Musawi AF; Al-Mulla A; Al-Dujaili AH; Debnath M; Maes M
    PLoS One; 2022; 17(10):e0275839. PubMed ID: 36256663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life.
    Maes M; Kanchanatawan B
    CNS Spectr; 2021 Apr; ():1-10. PubMed ID: 33843548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia phenomenology comprises a bifactorial general severity and a single-group factor, which are differently associated with neurotoxic immune and immune-regulatory pathways.
    Maes M; Vojdani A; Geffard M; Moreira EG; Barbosa DS; Michelin AP; Semeão LO; Sirivichayakul S; Kanchanatawan B
    Biomol Concepts; 2019 Nov; 10(1):209-225. PubMed ID: 31734647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.